title: The anticonvulsant valproate increases the turnover rate of gamma-aminobutyric acid transporters.
abstract: Valproate is an important anticonvulsant currently in clinical use for the treatment of seizures. We used electrophysiological and tracer uptake methods to examine the effect of valproate on a gamma-aminobutyric acid (GABA) transporter (mouse GAT3) expressed in Xenopus laevis oocytes. In the absence of GABA, valproate (up to 50 mm) had no noticeable effect on the steady-state electrogenic properties of mGAT3. In the presence of GABA, however, valproate enhanced the GABA-evoked steady-state inward current in a dose-dependent manner with a half-maximal concentration of 4.6 +/- 0.5 mm. Maximal enhancement of the GABA-evoked current was 275 +/- 10%. Qualitatively similar observations were obtained for human GAT1 and mouse GAT4. The valproate enhancement did not alter the Na(+) or Cl(-) dependence of the steady-state GABA-evoked currents. Uptake experiments under voltage clamp suggested that the valproate enhancement of the GABA-evoked current was matched by an enhancement in GABA uptake. Thus, despite the increase in GABA-evoked current, ion/GABA co-transport remained tightly coupled. Uptake experiments indicated that valproate is not transported by mouse GAT3 in the absence or presence of GABA. Valproate also enhanced the rate of the partial steps involved in transporter presteady-state charge movements. We propose that valproate increases the turnover rate of GABA transporters by an allosteric mechanism. The data suggest that at its therapeutic concentration, valproate may enhance the activity of neuronal and glial GABA transporters by up to 10%.
authors.affiliation: Biological Sciences Department, California State Polytechnic University, Pomona, California 91768-4032, USA.
authors.forename: Richard D
authors.initials: RD
authors.lastname: Whitlow
authors.forename: Ayelet
authors.initials: A
authors.lastname: Sacher
authors.forename: Donald D F
authors.initials: DD
authors.lastname: Loo
authors.forename: Nathan
authors.initials: N
authors.lastname: Nelson
authors.forename: Sepehr
authors.initials: S
authors.lastname: Eskandari
mesh_terms: D000818:Animals; D000927:Anticonvulsants / Q000494:pharmacology*; D001692:Biological Transport; D002352:Carrier Proteins / Q000378:metabolism; D002462:Cell Membrane / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004594:Electrophysiology; D050485:GABA Plasma Membrane Transport Proteins; D006801:Humans; D007477:Ions; D008565:Membrane Proteins / Q000378:metabolism; D026901:Membrane Transport Proteins / Q000378:metabolism*; D051379:Mice; D008954:Models, Biological; D009457:Neuroglia / Q000378:metabolism; D009474:Neurons / Q000378:metabolism; D027361:Organic Anion Transporters; D012965:Sodium Chloride / Q000494:pharmacology; D014635:Valproic Acid / Q000494:pharmacology*; D014982:Xenopus laevis
chemical_list: D000927:Anticonvulsants; D002352:Carrier Proteins; D050485:GABA Plasma Membrane Transport Proteins; D007477:Ions; D008565:Membrane Proteins; D026901:Membrane Transport Proteins; D027361:Organic Anion Transporters; D012965:Sodium Chloride; D014635:Valproic Acid; C079264:Slc6a11 protein, mouse; C493413:SLC6A1 protein, human; C493416:SLC6A11 protein, human; C493414:Slc6a1 protein, mouse; C493419:Slc6a13 protein, mouse